Olmesartan
- Generic Name
- Olmesartan
- Brand Names
- Azor, Benicar, Benicar Hct, Olmetec, Olmetec Plus, Tribenzor
- Drug Type
- Small Molecule
- Chemical Formula
- C24H26N6O3
- CAS Number
- 144689-24-7
- Unique Ingredient Identifier
- 8W1IQP3U10
- Background
Olmesartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes telmisartan, candesartan, losartan, valsartan, and irbesartan. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and syn...
- Indication
Olmesartan is indicated for the treatment of hypertension either alone or in combination with other antihypertensive agents.
...
- Associated Conditions
- Diabetic Nephropathy, Hypertension
- Associated Therapies
- -
Multi-Omics to Predict the Blood Pressure Response to Antihypertensives
- Conditions
- Interventions
- First Posted Date
- 2023-06-23
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 96
- Registration Number
- NCT05917275
- Locations
- π³π±
Radboudumc, Nijmegen, Netherlands
Effect of Olmesartan on Angiotensin(1-7) Levels and Vascular Functions in Diabetes and Hypertension
- Conditions
- Interventions
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Seoul National University Bundang Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT05189015
- Locations
- π°π·
Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of
Observational Study to Evaluate the Therapeutic Effectiveness and Safety of Olomax Tab
- Conditions
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Daewoong Pharmaceutical Co. LTD.
- Target Recruit Count
- 5450
- Registration Number
- NCT05184179
- Locations
- π°π·
Hallym University Dongtan Sacred Heart Hospital, Hwaseong-si, Gyeonggi, Korea, Republic of
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)
- Conditions
- Interventions
- First Posted Date
- 2021-11-02
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 672
- Registration Number
- NCT05103332
- Locations
- π¬π§
Clinical Trial Site, Torpoint, United Kingdom
πΊπΈClinical Trials Site, Beverly Hills, California, United States
πΊπΈClinical Trial site, Winston-Salem, North Carolina, United States
s086 Tablets in the Treatment of Mild to Moderate Essential Hypertension
- Conditions
- Interventions
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- Shenzhen People's Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT05033535
- Locations
- π¨π³
Shenzhen People' S Hospital, Shenzhen, Guangdong, China
Clinical Trial to Evaluate Pharmacokinetic Interaction of ATB-1011 and ATB-1012 in Healthy Adult Volunteers
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- Autotelicbio
- Target Recruit Count
- 38
- Registration Number
- NCT04856969
- Locations
- π°π·
H Plus Yangji Hospital, Seoul, Gwanak-gu, Korea, Republic of
Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?
- Conditions
- Interventions
- First Posted Date
- 2020-10-28
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 341
- Registration Number
- NCT04606563
- Locations
- π¨π¦
Royal Jubilee Hospital, Nanaimo, British Columbia, Canada
π¨π¦St Paul's Hospital, Vancouver, British Columbia, Canada
π¨π¦The Ottawa Hospital, Ottawa, Ontario, Canada
Effect of Olmesartan and Nebivolol on Ambulatory Blood Pressure and Arterial Stiffness in Acute Stage of Ischemic Stroke
- Conditions
- Interventions
- First Posted Date
- 2018-09-04
- Last Posted Date
- 2020-01-07
- Lead Sponsor
- Aristotle University Of Thessaloniki
- Target Recruit Count
- 60
- Registration Number
- NCT03655964
- Locations
- π¬π·
AHEPA University Hospital, Thessaloniki, Greece
Use of Impedance Cardiography and Applanation Tonometry for Prediction of the Antihypertensive Effect of Two Drugs
- Conditions
- Interventions
- First Posted Date
- 2018-06-18
- Last Posted Date
- 2018-06-18
- Lead Sponsor
- AHEPA University Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT03560804
- Locations
- π¬π·
Hypertension Excellence Center, AHEPA University Hospital, Thessaloniki, Greece
Efficacy of Olmesartan on Cerebral Glucose Metabolism, Vascular Inflammation and Adipose Tissue
- Conditions
- Interventions
- First Posted Date
- 2016-12-19
- Last Posted Date
- 2016-12-20
- Lead Sponsor
- Kurume University
- Target Recruit Count
- 100
- Registration Number
- NCT02996916
- Locations
- π―π΅
Kurume University Hospital, Kurume, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.